BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 11769882)

  • 1. An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):306-16. PubMed ID: 11769882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of NSAIDs for the chemoprevention of colorectal cancer.
    Herendeen JM; Lindley C
    Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
    Nasir A; Fernandez PM; Chughtai OR; Kaiser HE
    In Vivo; 2002; 16(6):501-9. PubMed ID: 12494894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevention of colorectal cancer by aspirin use.
    Giovannucci E
    Biomed Pharmacother; 1999 Aug; 53(7):303-8. PubMed ID: 10472428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma].
    Tuynman JB; Hulscher JB; Steller EP; van Lanschot JJ; Richel DJ
    Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2207-12. PubMed ID: 14640057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2 inhibition and prevention of cancer.
    Giercksky KE
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):821-33. PubMed ID: 11566043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
    Okajima E; Uemura H; Ohnishi S; Tanaka M; Ohta M; Tani M; Fujimoto K; Ozono S; Okajima E; Hirao Y
    Aktuelle Urol; 2003 Jul; 34(4):256-8. PubMed ID: 14566678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
    Gill S; Sinicrope FA
    Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
    Peek RM
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S50-6. PubMed ID: 15309515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.
    Gupta RA; Dubois RN
    Nat Rev Cancer; 2001 Oct; 1(1):11-21. PubMed ID: 11900248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA; Delafontaine P
    J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
    Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
    Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer.
    Pereg D; Lishner M
    J Intern Med; 2005 Aug; 258(2):115-23. PubMed ID: 16018788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review.
    Pruthi RS; Derksen E; Gaston K
    J Urol; 2003 Jun; 169(6):2352-9. PubMed ID: 12771797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
    Sanborn R; Blanke CD
    Semin Oncol; 2005 Feb; 32(1):69-75. PubMed ID: 15726508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors.
    Reddy BS; Rao CV
    J Environ Pathol Toxicol Oncol; 2002; 21(2):155-64. PubMed ID: 12086402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
    Sandler RS
    Important Adv Oncol; 1996; ():123-37. PubMed ID: 8791132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.